PMID- 16972260 OWN - NLM STAT- MEDLINE DCOM- 20070207 LR - 20131121 IS - 0021-9541 (Print) IS - 0021-9541 (Linking) VI - 209 IP - 3 DP - 2006 Dec TI - Homocysteine-induced myofibroblast differentiation in mouse aortic endothelial cells. PG - 767-74 AB - Differentiation of myofibroblast, as evidenced by alpha-smooth muscle actin (alpha-SMA) expression, is largely mediated by transforming growth factor-beta1 (TGF-beta1). This mechanism often follows inflammatory events such as endothelial damage due to oxidative stress, which can further leads to vascular thickening, stiffness, and fibrosis. We hypothesized that hyperhomocysteinemia (HHcy)-induced oxidative stress lead to vascular stiffness, in part due to endothelial-myofibroblast differentiation and alteration of collagen homeostasis in the extracellular matrix (ECM). We tested our hypothesis in vitro using mouse aortic endothelial cells (MAEC). Our result shows that Hcy induces alpha-SMA and collagen type-1 expression in MAEC as evidenced by immunoblot and confocal imaging. RT-PCR shows robust increase of alpha-SMA and collagen type-1 mRNA level in Hcy-induced condition. We demonstrated that Hcy induces autophosphorylation of focal adhesion kinase (FAK) (a member of the protein tyrosine kinase (PTK) family) at Tyr-397. PP2 (general PTK inhibitor) as well as FAK siRNA abrogates Hcy-mediated alpha-SMA formation. In addition to that, Hcy-mediated TGF-beta1 induction was inhibited by TGF-beta R1 kinase inhibitor II (ALK5 inhibitor II) and attenuated FAK phosphorylation and alpha-SMA expression. Furthermore, we showed that Hcy activates ERK-44/42 (extracellular signal-regulated kinase) pathway and augments collagen type-1 deposition. Studies with pharmacological ERK blocker, PD98059 and ERK siRNA attenuated ERK-44/42 phosphorylation and collagen type-1 synthesis. Taken together our results demonstrate that Hcy-mediated TGF-beta1 upregulation triggers endothelial-myofibroblast differentiation secondary to FAK phosphorylation and that Hcy-induced ERK activation is involved in ECM remodeling by altering collagen type-1 homeostasis. CI - (c) 2006 Wiley-Liss, Inc. FAU - Sen, Utpal AU - Sen U AD - Department of Physiology & Biophysics, HSC, University of Louisville School of Medicine, 500 South Preston St., Louisville, KY 40202, USA. FAU - Moshal, Karni S AU - Moshal KS FAU - Tyagi, Neetu AU - Tyagi N FAU - Kartha, Ganesh K AU - Kartha GK FAU - Tyagi, Suresh C AU - Tyagi SC LA - eng GR - HL 71010/HL/NHLBI NIH HHS/United States GR - HL 74185/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - J Cell Physiol JT - Journal of cellular physiology JID - 0050222 RN - 0 (Actins) RN - 0 (Collagen Type I) RN - 0 (Enzyme Inhibitors) RN - 0 (RNA, Small Interfering) RN - 0 (Transforming Growth Factor beta1) RN - 0LVT1QZ0BA (Homocysteine) RN - EC 2.7.10.2 (Focal Adhesion Kinase 1) RN - EC 2.7.10.2 (Ptk2 protein, mouse) RN - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases) SB - IM MH - Actins/genetics/metabolism MH - Animals MH - Aorta/*cytology MH - Cell Differentiation/*drug effects MH - Cells, Cultured MH - Collagen Type I/genetics/metabolism MH - Endothelial Cells/cytology/drug effects/*physiology MH - Enzyme Induction MH - Enzyme Inhibitors/metabolism MH - Extracellular Signal-Regulated MAP Kinases/metabolism MH - Fibroblasts/cytology/drug effects/*physiology MH - Focal Adhesion Kinase 1/metabolism MH - *Homocysteine/metabolism/pharmacology MH - Mice MH - RNA, Small Interfering/genetics/metabolism MH - Transforming Growth Factor beta1/metabolism EDAT- 2006/09/15 09:00 MHDA- 2007/02/08 09:00 CRDT- 2006/09/15 09:00 PHST- 2006/09/15 09:00 [pubmed] PHST- 2007/02/08 09:00 [medline] PHST- 2006/09/15 09:00 [entrez] AID - 10.1002/jcp.20752 [doi] PST - ppublish SO - J Cell Physiol. 2006 Dec;209(3):767-74. doi: 10.1002/jcp.20752.